These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

545 related items for PubMed ID: 17525183

  • 1. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.
    Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, Cursiefen C.
    Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2545-52. PubMed ID: 17525183
    [Abstract] [Full Text] [Related]

  • 2. Topical Ranibizumab inhibits inflammatory corneal hem- and lymphangiogenesis.
    Bucher F, Parthasarathy A, Bergua A, Onderka J, Regenfuss B, Cursiefen C, Bock F.
    Acta Ophthalmol; 2014 Mar; 92(2):143-8. PubMed ID: 22994268
    [Abstract] [Full Text] [Related]

  • 3. Serum eyedrops antagonize the anti(lymph)angiogenic effects of bevacizumab in vitro and in vivo.
    Hos D, Koch KR, Bucher F, Bock F, Cursiefen C, Heindl LM.
    Invest Ophthalmol Vis Sci; 2013 Sep 11; 54(9):6133-42. PubMed ID: 23970469
    [Abstract] [Full Text] [Related]

  • 4. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation.
    Hos D, Bock F, Dietrich T, Onderka J, Kruse FE, Thierauch KH, Cursiefen C.
    Invest Ophthalmol Vis Sci; 2008 May 11; 49(5):1836-42. PubMed ID: 18436817
    [Abstract] [Full Text] [Related]

  • 5. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
    Chen WL, Lin CT, Lin NT, Tu IH, Li JW, Chow LP, Liu KR, Hu FR.
    Invest Ophthalmol Vis Sci; 2009 Apr 11; 50(4):1659-65. PubMed ID: 18997093
    [Abstract] [Full Text] [Related]

  • 6. Sunitinib inhibits inflammatory corneal lymphangiogenesis.
    Detry B, Blacher S, Erpicum C, Paupert J, Maertens L, Maillard C, Munaut C, Sounni NE, Lambert V, Foidart JM, Rakic JM, Cataldo D, Noël A.
    Invest Ophthalmol Vis Sci; 2013 May 03; 54(5):3082-93. PubMed ID: 23580490
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
    Kim TI, Kim SW, Kim S, Kim T, Kim EK.
    Cornea; 2008 Apr 03; 27(3):349-52. PubMed ID: 18362666
    [Abstract] [Full Text] [Related]

  • 9. Doxycycline enhances the inhibitory effects of bevacizumab on corneal neovascularization and prevents its side effects.
    Su W, Li Z, Li Y, Lin M, Yao L, Liu Y, He Z, Wu C, Liang D.
    Invest Ophthalmol Vis Sci; 2011 Nov 25; 52(12):9108-15. PubMed ID: 22039247
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Interaction between bevacizumab and murine VEGF-A: a reassessment.
    Yu L, Wu X, Cheng Z, Lee CV, LeCouter J, Campa C, Fuh G, Lowman H, Ferrara N.
    Invest Ophthalmol Vis Sci; 2008 Feb 25; 49(2):522-7. PubMed ID: 18234994
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Safety profile of topical VEGF neutralization at the cornea.
    Bock F, Onderka J, Rummelt C, Dietrich T, Bachmann B, Kruse FE, Schlötzer-Schrehardt U, Cursiefen C.
    Invest Ophthalmol Vis Sci; 2009 May 25; 50(5):2095-102. PubMed ID: 19151400
    [Abstract] [Full Text] [Related]

  • 18. The effect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits.
    Kang S, Chung SK.
    Cornea; 2010 Feb 25; 29(2):192-6. PubMed ID: 20098156
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids.
    Hos D, Saban DR, Bock F, Regenfuss B, Onderka J, Masli S, Cursiefen C.
    Arch Ophthalmol; 2011 Apr 25; 129(4):445-52. PubMed ID: 21482870
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.